1) What is the number of patients in the last 12 months treated with the following product lines:
A) anidulafungin
B) caspofungin
C) micafungin
2) What is the split of indication over the last 12 months for the following product lines:
A) anidulafungin
B) caspofungin
C) micafungin
3) For each of the indication splits of the 3 product lines mentioned previously (anidulafungin, caspofungin and micafungin from Q2), please list the average length of treatment time.